These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34677803)

  • 1. Severe and Difficult Asthma: Diagnosis and Management-Challenges for a Low-Resource Environment.
    Bush A
    Indian J Pediatr; 2022 Feb; 89(2):156-162. PubMed ID: 34677803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. This Child's Asthma Appears to Be Severe: But Where Actually Is the Severe Problem?
    Bush A
    Acta Med Acad; 2020 Aug; 49(2):103-116. PubMed ID: 33189117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Management of Problematic Severe Asthma.
    Scotney E; Saglani S
    Acta Med Acad; 2020 Aug; 49(2):117-129. PubMed ID: 33189118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dark side of the moon: severe therapy-resistant asthma in children.
    de Benedictis FM; Carloni I; Bush A
    Monaldi Arch Chest Dis; 2012 Jun; 77(2):83-93. PubMed ID: 23193845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe asthma in children.
    Bush A; Fleming L; Saglani S
    Respirology; 2017 Jul; 22(5):886-897. PubMed ID: 28543931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.
    Mirra V; Montella S; Santamaria F
    BMC Pediatr; 2018 Feb; 18(1):73. PubMed ID: 29466963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
    J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
    Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
    J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe asthma in childhood: diagnostic and management challenges.
    Bozzetto S; Carraro S; Zanconato S; Baraldi E
    Curr Opin Pulm Med; 2015 Jan; 21(1):16-21. PubMed ID: 25415405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
    Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
    Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
    Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating asthma by the guidelines: developing a medication management information system for use in primary care.
    Twiggs JE; Fifield J; Jackson E; Cushman R; Apter A
    Dis Manag; 2004; 7(3):244-60. PubMed ID: 15669584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
    Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
    J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.